Efficacy of Japanese cedar pollen sublingual immunotherapy tablets for Japanese cypress pollinosis
Journal of Allergy and Clinical Immunology: Global · 2023-05 · 2 (2) · 100075
DOI: 10.1016/j.jacig.2022.10.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2023-05. Verfasst von Tomoya Kurokawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Torii Pharmaceutical Co Ltd.
Abstract (Originalsprache)
Background
We previously demonstrated the efficacy of Japanese cedar (JC) pollen sublingual immunotherapy (SLIT) tablets for treating seasonal allergic rhinitis in a clinical trial (trial no. 206-2-1) that covered 5 pollen dispersal seasons from 2015 to 2019.
Objective
Our aim was to perform post hoc analysis of the 206-2-1 trial data to evaluate the efficacy of JC pollen SLIT tablets for patients with rhinitis induced by pollen from Japanese cypress (JCY), a related Cupressaceae species that has a pollen dispersal season overlapping with that of JC.
Methods
Data were analyzed for 240 patients who received placebo during the first pollen dispersal season in 2015, were then rerandomized to receive JC SLIT tablets (the PA group) or placebo (the PP group) for 18 months (the 2016 and 2017 dispersal seasons), and were observed untreated for 2 years (the 2018 and 2019 dispersal seasons). The PA and PP groups were assigned to "high" and "low" subgroups if their rhinitis symptoms were exacerbated/did not change or decreased, respectively, during the peak JCY pollen dispersal period in 2015. The mean total nasal symptom and medication scores and other outcomes were compared for the high-PP, high-PA, low-PP, and low-PA groups during the 2016 to 2019 peak JCY pollen dispersal periods.
Results
The mean total nasal symptom and medication scores were significantly lower for the high-PA and low-PA groups than for the corresponding PP groups over the 4 years of treatment and observation. JCY pollen-specific IgE levels increased in both PA groups.
Conclusion
JC pollen SLIT tablets effectively suppressed JCY pollinosis symptoms, supporting the clinical relevance of immunologic cross-reactivity between JC and JCY allergens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Clinical Research Center, Chiba University Hospital, Chiba, Japan.
- Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
- Department of Otorhinolaryngology, International University of Health and Welfare, Chiba, Japan.
- Department of Medical Affairs, Torii Pharmaceutical Co, Ltd, Tokyo, Japan.
- Chiba Rousai Hospital, Chiba, Japan.
Förderung
- Torii Pharmaceutical Co Ltd
Zitieren
APA
Kurokawa, T., Yonekura, S., Gotoh, M., Okano, M., Maekawa, Y., Okubo, K., & Okamoto, Y. (2023). Efficacy of Japanese cedar pollen sublingual immunotherapy tablets for Japanese cypress pollinosis. Journal of Allergy and Clinical Immunology: Global, 2(2), 100075. https://doi.org/10.1016/j.jacig.2022.10.006
Vancouver
Kurokawa T, Yonekura S, Gotoh M, Okano M, Maekawa Y, Okubo K, et al. Efficacy of Japanese cedar pollen sublingual immunotherapy tablets for Japanese cypress pollinosis. Journal of Allergy and Clinical Immunology: Global. 2023;2(2):100075. doi:10.1016/j.jacig.2022.10.006
BibTeX
@article{Kurokawa2023,
author = {Kurokawa, Tomoya and Yonekura, Syuji and Gotoh, Minoru and Okano, Mitsuhiro and Maekawa, Yuriko and Okubo, Kimihiro and Okamoto, Yoshitaka},
title = {Efficacy of Japanese cedar pollen sublingual immunotherapy tablets for Japanese cypress pollinosis},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2023},
volume = {2},
number = {2},
pages = {100075},
doi = {10.1016/j.jacig.2022.10.006}
}
EUVIMED